Annual cholangiocarcinoma incidence in PSC

What is known

• A comprehensive review reports an annual incidence of 0.5 to 1.5 per 100 persons, nearly 10 to 1000 times higher than the general population. ¹
• A cohort of 161 PSC patients followed for a median of 11.5 years found CCA developed at approximately 0.6% per year, with a markedly increased relative risk. ²
• One review cites a global annual incidence of about 500 per 100,000 PSC patients (0.5% annually), roughly 400 times the general-population risk. ³
• 30-50% of CCA in PSC are diagnosed within the first year after PSC diagnosis; reported lifetime risk ranges from about 5% to 20%. ^1,4,5

What is unknown / caveats

• One review reports much higher figures (~7 - 9%, up to 20% in North America and highest in Asia), but these are cumulative proportions of PSC cohorts developing CCA rather than annual rates, and are consistent with the lifetime risk of about 5% to 20% given above rather than with the annual 0.5 - 1.5%
• Marked variability in reported incidence across studies and regions
• Lifetime estimates derived from limited longitudinal data may underestimate true risk
• Estimates vary substantially by population and study methodology, and the reasons for regional differences (e.g., higher rates in Asia) are unknown.

References

1. Song J, Li Y, Bowlus CL, Yang G, Leung PSC, Gershwin ME. Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review. Clin Rev Allergy Immunol. 2020. PMID: 31463807.

2. Burak K, Angulo P, Pasha Tousif M, Egan K, Petz J, Lindor Keith D. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99:523-6. PMID: 15056096.

3. Mehta TI, Weissman S, Fung BM, Tabibian JH. Geoepidemiologic variation in outcomes of primary sclerosing cholangitis. World J Hepatol. 2020. PMID: 32685104.

4. Horsley-Silva JL, Rodriguez EA, Franco DL, Lindor KD. An update on cancer risk and surveillance in primary sclerosing cholangitis. Liver Int. 2017. PMID: 28028930.

5. Fung BM, Lindor KD, Tabibian JH. Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies. World J Gastroenterol. 2019. PMID: 30783370.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.